Spending on point-of-care drug marketing has surged, with revenues from members of the Point of Care Marketing Association increasing by 16% last year, surpassing the $1 billion threshold. This significant growth highlights a shift in marketing strategies as pharmaceutical companies increasingly recognize the value of engaging healthcare professionals at the point of care.
The rise in spending reflects a broader trend within the industry, where direct engagement with prescribers at the time of patient interaction is becoming a critical component of marketing efforts. As healthcare becomes more complex, the need for timely and relevant information at the point of care is paramount, leading to increased investment in targeted marketing initiatives.
Sponsored: API & FDF Intelligence is a strategic resource for analysts and investors. Beyond APIs, FDFs, and excipients, the platform provides visibility into price trends, dossier portfolios, geographic concentration of suppliers, and supply chain vulnerabilities. It helps identify open opportunities, compare API and FDF price ranges by region, and evaluate risks for deals and investments. Direct company contacts are included, enabling on-the-ground verification. All of this is available immediately upon subscription — starting at just $42/month for individual users. Learn more.
This milestone not only underscores the growing importance of point-of-care marketing but also signals potential shifts in resource allocation among pharmaceutical companies. As competition intensifies, firms may need to reevaluate their marketing strategies to ensure they are effectively reaching healthcare providers and influencing prescribing behavior at crucial moments.
